Melissa J Peart
Overview
Explore the profile of Melissa J Peart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peart M, Poyurovsky M, Kass E, Urist M, Verschuren E, Summers M, et al.
Cell Cycle
. 2010 Oct;
9(19):3956-64.
PMID: 20948288
The mechanisms that control E2F-1 activity are complex. We previously showed that Chk1 and Chk2 are required for E2F1 stabilization and p73 target gene induction following DNA damage. To gain...
2.
Beckerman R, Donner A, Mattia M, Peart M, Manley J, Espinosa J, et al.
Genes Dev
. 2009 Jun;
23(11):1364-77.
PMID: 19487575
We reported previously that when cells are arrested in S phase, a subset of p53 target genes fails to be strongly induced despite the presence of high levels of p53....
3.
Li Y, Peart M, Prives C
Mol Cell Biol
. 2009 May;
29(14):3953-63.
PMID: 19451233
p63, a member of the p53 tumor suppressor family, is essential for the development of epidermis as well as other stratified epithelia. Collective evidence indicates that DeltaNp63 proteins, the N-terminally...
4.
Whitecross K, Alsop A, Cluse L, Wiegmans A, Banks K, Coomans C, et al.
Blood
. 2008 Dec;
113(9):1982-91.
PMID: 19060243
The apoptotic and therapeutic activities of the histone deacetylase inhibitor (HDACi) vorinostat are blocked by overexpression of Bcl-2 or Bcl-X(L). Herein, we used the small molecule inhibitor ABT-737 to restore...
5.
Li H, Okamoto K, Peart M, Prives C
Mol Cell Biol
. 2008 Nov;
29(3):919-28.
PMID: 18981217
Although the cyclin G1 gene is known to be regulated at the transcriptional level by p53, less is understood about the turnover of its protein product. We found that ectopically...
6.
Peart M, Prives C
Cancer Cell
. 2006 Sep;
10(3):173-4.
PMID: 16959607
The molecular mechanisms underlying mutant p53 gain of function are becoming increasingly complex. In this issue of Cancer Cell, Di Agostino et al. identify the heterotrimeric transcription factor NF-Y as...
7.
Bolden J, Peart M, Johnstone R
Nat Rev Drug Discov
. 2006 Sep;
5(9):769-84.
PMID: 16955068
Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression. In addition, the activity of non-histone proteins...
8.
Peart M, Smyth G, van Laar R, Bowtell D, Richon V, Marks P, et al.
Proc Natl Acad Sci U S A
. 2005 Mar;
102(10):3697-702.
PMID: 15738394
Histone deacetylase inhibitors (HDACis) inhibit tumor cell growth and survival, possibly through their ability to regulate the expression of specific proliferative and/or apoptotic genes. However, the HDACi-regulated genes necessary and/or...
9.
Peart M, Tainton K, Ruefli A, Dear A, Sedelies K, OReilly L, et al.
Cancer Res
. 2003 Aug;
63(15):4460-71.
PMID: 12907619
Histone deacetylase inhibitors (HDACIs) are a new class of chemotherapeutic drugs able to induce tumor cell apoptosis and/or cell cycle arrest; however, the molecular mechanisms underpinning their anticancer effects are...